The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1088 Ozempic articles
A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.
New data suggests Eli Lilly's retatrutide could deliver up to 28% weight loss, potentially rivaling bariatric surgery. Learn about efficacy and safety.
Women achieving significant weight loss on GLP-1 medications like Ozempic or Wegovy often report unexpected side effects—worsening hot flashes, sleep disruption, and mood swings—that mimic or accelerate menopause symptoms. This article explores the crucial, often overlooked, intersection between rapid fat loss and hormonal balance.
The growing popularity of GLP-1 medications, including Wegovy, is having a notable impact on retail spending, particularly in the pharmaceutical sector. This article delves into the economic implications and what it means for consumers and businesses.
Popular GLP-1 medications, known for their weight loss efficacy, are now showing potential to combat arthritis inflammation. Discover what this groundbreaking research means for joint health.
Concerns are mounting over the integrity of the pharmaceutical supply chain as the FDA takes action against a Chinese supplier for questionable practices involving critical GLP-1 drug ingredients. This development raises questions about the safety and reliability of active pharmaceutical ingredients used in popular weight loss and diabetes medications.
The launch of GLP-1 agonists like Ozempic and Wegovy has not only transformed weight management but also sparked an unexpected trend: a significant increase in vitamin supplement sales. This article delves into the potential reasons behind this phenomenon and what it signifies for individuals managing their health with these powerful medications.
Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.
Eli Lilly's Retatrutide has shown remarkable weight loss potential in Phase 3 trials. We break down the TRIUMPH-1 results, safety data, and what patients can expect.
